Kateřina Menšíková
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kateřina Menšíková has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Petr Kaňovský
Department of Neurology and Clinical Neuroscience Center, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
16 shared publications - Radek Vodicka
Department of Clinical Genetics, University Hospital Olomouc, Olomouc, Czech Republic
8 shared publications Petr Kaňovský
Olomouc
6 shared publicationsLucie Tučková
Department of Neurology, University Hospital, Palacky University, Olomouc, Czech Republic
5 shared publicationsPavel Otruba
Department of Neurology and Clinical Neuroscience Center, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
5 shared publicationsRadoslav Matěj
5 shared publications
Latest Publications
- Open Access
- 27 April 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (2)
Correction: Cutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups
- 27 April 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (2)
Open AccessCorrection: Cutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups
- Open Access
- 6 April 2026
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (7) , 1105-1120
Genetic and environmental risk factors of Parkinsonism
Parkinsonian disorders comprise a broad spectrum of neurodegenerative diseases with a wide variety of pathogenetic processes. These processes lead to the formation of pathological proteins, resulting in the brain diseases called synucleinopathies, tauopathies or TDP-43 proteinopathies. There is currently growing support for the hypothesis that genetic variants explain a significant fraction of the etiology of apparently sporadic parkinsonian disorders. Genetic risk factors can be stratified according to the metabolic or structural processes that can lead to cellular disturbance; these processes involve protein aggregation, protein and membrane trafficking, stabilization of the neurite structure, prion-like transmission of pathological proteins, ubiquitin–proteasome system balance, mitophagy, lysosome autophagy, synaptic functions, and dopamine transmission. Regarding the environmental risk factors, there are several substances that have been supposed of being a risk for the development of neurodegenerative proteinopathy and Parkinsonism, mainly the agents used in agriculture and the textile industry. The most important and most frequently studied are pesticides and trichlorethylene. Beside the globally ubiquitous substances which are supposedly neurotoxic and exposure to which can cause manifestations of Parkinsonism, there are more geographically (regionally) specific substances, which cause (or quite recently caused) the manifestation of endemically present Parkinsonism. Among ten types of endemic Parkinsonism, three of them are thought to have an environmental cause: Western Pacific Parkinsonism, Caribbean Parkinsonism, and North France cluster of atypical Parkinsonism.
- 6 April 2026
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (7) , 1105-1120
Open AccessGenetic and environmental risk factors of Parkinsonism
Parkinsonian disorders comprise a broad spectrum of neurodegenerative diseases with a wide variety of pathogenetic processes. These processes lead to the formation of pathological proteins, resulting in the brain diseases called synucleinopathies, tauopathies or TDP-43 proteinopathies. There is currently growing support for the hypothesis that genetic variants explain a significant fraction of the etiology of apparently sporadic parkinsonian disorders. Genetic risk factors can be stratified according to the metabolic or structural processes that can lead to cellular disturbance; these processes involve protein aggregation, protein and membrane trafficking, stabilization of the neurite structure, prion-like transmission of pathological proteins, ubiquitin–proteasome system balance, mitophagy, lysosome autophagy, synaptic functions, and dopamine transmission. Regarding the environmental risk factors, there are several substances that have been supposed of being a risk for the development of neurodegenerative proteinopathy and Parkinsonism, mainly the agents used in agriculture and the textile industry. The most important and most frequently studied are pesticides and trichlorethylene. Beside the globally ubiquitous substances which are supposedly neurotoxic and exposure to which can cause manifestations of Parkinsonism, there are more geographically (regionally) specific substances, which cause (or quite recently caused) the manifestation of endemically present Parkinsonism. Among ten types of endemic Parkinsonism, three of them are thought to have an environmental cause: Western Pacific Parkinsonism, Caribbean Parkinsonism, and North France cluster of atypical Parkinsonism.
- Open Access
- 21 February 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (1) , 37
Cutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups
There is an urgent need for early and accurate biomarkers of neurodegenerative disorders. Due to the high innervation and accessibility of the skin, a skin biopsy is a minimally invasive method of detecting phosphorylated α-synuclein (p-α-syn) and assessing intraepidermal nerve fiber density (IENFD). We analyzed biopsies taken from the back and the leg of patients with parkinsonian syndromes (Park.sy.), α-synucleinopathies, multiple system atrophies (MSA), tauopathies, and other neurological disorders, as well as from healthy controls. Double immunofluorescence was performed for p-α-syn (Ser129) and protein gene product 9.5 (PGP 9.5), alongside quantitative IENFD assessment. p-α-syn was significantly more prevalent in the patient groups than in the control group. The highest prevalence was observed in patients with parkinsonian syndromes, α-synucleinopathies and MSA. Tauopathies showed preferential paravertebral positivity. Reduction or absence of IENFD was most pronounced in tauopathies (75%), while IENFD was most commonly preserved in MSA (83.3%), indicating that disease-specific patterns of peripheral nerve involvement are exhibited. p-α-syn positivity was found to correlate with shorter disease duration, suggesting its potential as an early biomarker. Combined with olfactory testing, cutaneous markers improved diagnostic discrimination. Our findings support the use of skin biopsies as a promising clinical tool in diagnosing biomarker-based neurodegenerative diseases.
- 21 February 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (1) , 37
Open AccessCutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups
There is an urgent need for early and accurate biomarkers of neurodegenerative disorders. Due to the high innervation and accessibility of the skin, a skin biopsy is a minimally invasive method of detecting phosphorylated α-synuclein (p-α-syn) and assessing intraepidermal nerve fiber density (IENFD). We analyzed biopsies taken from the back and the leg of patients with parkinsonian syndromes (Park.sy.), α-synucleinopathies, multiple system atrophies (MSA), tauopathies, and other neurological disorders, as well as from healthy controls. Double immunofluorescence was performed for p-α-syn (Ser129) and protein gene product 9.5 (PGP 9.5), alongside quantitative IENFD assessment. p-α-syn was significantly more prevalent in the patient groups than in the control group. The highest prevalence was observed in patients with parkinsonian syndromes, α-synucleinopathies and MSA. Tauopathies showed preferential paravertebral positivity. Reduction or absence of IENFD was most pronounced in tauopathies (75%), while IENFD was most commonly preserved in MSA (83.3%), indicating that disease-specific patterns of peripheral nerve involvement are exhibited. p-α-syn positivity was found to correlate with shorter disease duration, suggesting its potential as an early biomarker. Combined with olfactory testing, cutaneous markers improved diagnostic discrimination. Our findings support the use of skin biopsies as a promising clinical tool in diagnosing biomarker-based neurodegenerative diseases.
- Open Access
- 13 February 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (3) , 261-274
The Amnesia Light and Brief Assessment (ALBA) and the door PICture Naming and Immediate Recall (PICNIR) brief tests for identifying mild cognitive impairment in Parkinson's disease
The Amnesia Light and Brief Assessment (ALBA) and the door PICture Naming and Immediate Recall (PICNIR) brief tests for identifying mild cognitive impairment in Parkinson
- 13 February 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (3) , 261-274
Open AccessThe Amnesia Light and Brief Assessment (ALBA) and the door PICture Naming and Immediate Recall (PICNIR) brief tests for identifying mild cognitive impairment in Parkinson's disease
The Amnesia Light and Brief Assessment (ALBA) and the door PICture Naming and Immediate Recall (PICNIR) brief tests for identifying mild cognitive impairment in Parkinson
- 30 July 2025
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 176, 106310
Metabolomics: Potential non-protein biomarker candidates of Parkinson's disease
- 30 July 2025
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 176, 106310
Metabolomics: Potential non-protein biomarker candidates of Parkinson's disease
- Open Access
- 21 November 2024
- Published by Cambridge University Press (CUP) in Nutrition Research Reviews
- Vol. 38 (2) , 540-545
Effects of active compounds and their metabolites associated with coffee consumption on neurodegenerative disease
Coffee is one of the most known and consumed beverages worldwide. Only three species are used in commercial coffee production, that is, Coffea arabica L. (Arabica coffee), Coffea canephora Pierre ex A. Froehner (Robusta coffee) and Coffea liberica Hiern (Excelsa coffee). The world population consumes approximately two billion cups of coffee per day, making it an important commercial resource of bioactive compounds in world markets. High interest in coffee consumption described in the literature is due not only to its organoleptic properties (for example, desirable bitterness, amount of flavours and aromas) but also to its ability to stimulate the central nervous system. It is now known that there are more than 1000 compounds in coffee beverages, several of which have a bioactive activity. Recent studies show that consuming three to four cups of coffee per day, that is, moderate consumption according to the European Food Safety Authority, may be beneficial for health. The main objective of the proposed review is to provide a comprehensive overview of bioactive compounds in coffee and other caffeine-containing beverages and their effects on neurodegenerative proteinopathies.
- 21 November 2024
- Published by Cambridge University Press (CUP) in Nutrition Research Reviews
- Vol. 38 (2) , 540-545
Open AccessEffects of active compounds and their metabolites associated with coffee consumption on neurodegenerative disease
Coffee is one of the most known and consumed beverages worldwide. Only three species are used in commercial coffee production, that is, Coffea arabica L. (Arabica coffee), Coffea canephora Pierre ex A. Froehner (Robusta coffee) and Coffea liberica Hiern (Excelsa coffee). The world population consumes approximately two billion cups of coffee per day, making it an important commercial resource of bioactive compounds in world markets. High interest in coffee consumption described in the literature is due not only to its organoleptic properties (for example, desirable bitterness, amount of flavours and aromas) but also to its ability to stimulate the central nervous system. It is now known that there are more than 1000 compounds in coffee beverages, several of which have a bioactive activity. Recent studies show that consuming three to four cups of coffee per day, that is, moderate consumption according to the European Food Safety Authority, may be beneficial for health. The main objective of the proposed review is to provide a comprehensive overview of bioactive compounds in coffee and other caffeine-containing beverages and their effects on neurodegenerative proteinopathies.
- Open Access
- 15 July 2024
- Published by Solen s.r.o. in Klinická farmakologie a farmacie
- Vol. 38 (2) , 60-66
Modern pharmacotherapy of Parkinson's disease
L??ba Parkinsonovy nemoci je v sou?asnosti st?le l??bou symptomatickou a jej? management je prim?rn? zam??en na kontrolu motorick?ch projev?. Hlavn?m pil??em sou?asn? terapie z?st?vaj? dopaminergn? prepar?ty nahrazuj?c? p?soben? chyb?j?c?ho do... L??ba Parkinsonovy nemoci je v sou?asnosti st?le l??bou symptomatickou a jej? management je prim?rn? zam??en na kontrolu motorick?ch projev?. Hlavn?m pil??em sou?asn? terapie z?st?vaj? dopaminergn? prepar?ty nahrazuj?c? p?soben? chyb?j?c?ho do...
- 15 July 2024
- Published by Solen s.r.o. in Klinická farmakologie a farmacie
- Vol. 38 (2) , 60-66
Open AccessModern pharmacotherapy of Parkinson's disease
L??ba Parkinsonovy nemoci je v sou?asnosti st?le l??bou symptomatickou a jej? management je prim?rn? zam??en na kontrolu motorick?ch projev?. Hlavn?m pil??em sou?asn? terapie z?st?vaj? dopaminergn? prepar?ty nahrazuj?c? p?soben? chyb?j?c?ho do... L??ba Parkinsonovy nemoci je v sou?asnosti st?le l??bou symptomatickou a jej? management je prim?rn? zam??en na kontrolu motorick?ch projev?. Hlavn?m pil??em sou?asn? terapie z?st?vaj? dopaminergn? prepar?ty nahrazuj?c? p?soben? chyb?j?c?ho do...
- Open Access
- 6 March 2024
- Published by Solen s.r.o. in Neurologie pro praxi
- Vol. 25 (1) , 36-40
Creutzfeldt-Jakob disease phenocopy
Creutzfeldtova?‑Jakobova nemoc (CJD) m??e m?t velmi r?znorodou klinickou manifestaci. Z?rove? st?le p?ib?v? neuropatologick?ch d?kaz? o nar?staj?c?m mno?stv? p??pad?, jejich? obraz spl?uje klinick? diagnostick? krit?ria "mo?n?"... Creutzfeldtova?‑Jakobova nemoc (CJD) m??e m?t velmi r?znorodou klinickou manifestaci. Z?rove? st?le p?ib?v? neuropatologick?ch d?kaz? o nar?staj?c?m mno?stv? p??pad?, jejich? obraz spl?uje klinick? diagnostick? krit?ria "mo?n?"...
- 6 March 2024
- Published by Solen s.r.o. in Neurologie pro praxi
- Vol. 25 (1) , 36-40
Open AccessCreutzfeldt-Jakob disease phenocopy
Creutzfeldtova?‑Jakobova nemoc (CJD) m??e m?t velmi r?znorodou klinickou manifestaci. Z?rove? st?le p?ib?v? neuropatologick?ch d?kaz? o nar?staj?c?m mno?stv? p??pad?, jejich? obraz spl?uje klinick? diagnostick? krit?ria "mo?n?"... Creutzfeldtova?‑Jakobova nemoc (CJD) m??e m?t velmi r?znorodou klinickou manifestaci. Z?rove? st?le p?ib?v? neuropatologick?ch d?kaz? o nar?staj?c?m mno?stv? p??pad?, jejich? obraz spl?uje klinick? diagnostick? krit?ria "mo?n?"...
- 9 February 2024
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 20 (3) , 195-196
Reply to: Questioning the cycad theory of Kii ALS–PDC causation
- 9 February 2024
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 20 (3) , 195-196
Reply to: Questioning the cycad theory of Kii ALS–PDC causation
- 8 September 2023
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 19 (10) , 599-616
Endemic parkinsonism: clusters, biology and clinical features
The term ‘endemic parkinsonism’ refers to diseases that manifest with a dominant parkinsonian syndrome, which can be typical or atypical, and are present only in a particular geographically defined location or population. Ten phenotypes of endemic parkinsonism are currently known: three in the Western Pacific region; two in the Asian-Oceanic region; one in the Caribbean islands of Guadeloupe and Martinique; and four in Europe. Some of these disease entities seem to be disappearing over time and therefore are probably triggered by unique environmental factors. By contrast, other types persist because they are exclusively genetically determined. Given the geographical clustering and potential overlap in biological and clinical features of these exceptionally interesting diseases, this Review provides a historical reference text and offers current perspectives on each of the 10 phenotypes of endemic parkinsonism. Knowledge obtained from the study of these disease entities supports the hypothesis that both genetic and environmental factors contribute to the development of neurodegenerative diseases, not only in endemic parkinsonism but also in general. At the same time, this understanding suggests useful directions for further research in this area.
- 8 September 2023
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 19 (10) , 599-616
Endemic parkinsonism: clusters, biology and clinical features
The term ‘endemic parkinsonism’ refers to diseases that manifest with a dominant parkinsonian syndrome, which can be typical or atypical, and are present only in a particular geographically defined location or population. Ten phenotypes of endemic parkinsonism are currently known: three in the Western Pacific region; two in the Asian-Oceanic region; one in the Caribbean islands of Guadeloupe and Martinique; and four in Europe. Some of these disease entities seem to be disappearing over time and therefore are probably triggered by unique environmental factors. By contrast, other types persist because they are exclusively genetically determined. Given the geographical clustering and potential overlap in biological and clinical features of these exceptionally interesting diseases, this Review provides a historical reference text and offers current perspectives on each of the 10 phenotypes of endemic parkinsonism. Knowledge obtained from the study of these disease entities supports the hypothesis that both genetic and environmental factors contribute to the development of neurodegenerative diseases, not only in endemic parkinsonism but also in general. At the same time, this understanding suggests useful directions for further research in this area.